A single arm phase 2 study of talimogene laherparepvec in patients with low-risk invasive cutaneous squamous cell cancer. interim analysis

e21583Background: A compromised immune-surveillance plays an important role in the pathogenesis of cutaneous squamous cell carcinoma (cSCC). Talimogene laherparepvec (TVEC) is an HSV-1 oncolytic immunological agent FDA approved for the local treatment of unresectable recurrent melanoma. It is propos...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 40; no. 16_suppl; p. e21583
Main Authors Curiel, Clara N, Stratton, Delaney, Cui, Haiyan, Roe, Denise, Arif Tiwari, Hina, Sundararajan, Srinath
Format Journal Article
LanguageEnglish
Published American Society of Clinical Oncology 01.06.2022
Online AccessGet full text
ISSN0732-183X
1527-7755
DOI10.1200/JCO.2022.40.16_suppl.e21583

Cover